Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody

F Tanaka, Y Otake, K Yanagihara, Y Kawano… - Clinical Cancer …, 2001 - AACR
F Tanaka, Y Otake, K Yanagihara, Y Kawano, R Miyahara, M Li, T Yamada, N Hanaoka…
Clinical Cancer Research, 2001AACR
Purpose: Angiogenesis is an essential process in the progression of malignant tumors.
Whereas pan-endothelial markers, such as CD34, are generally used in evaluation of
angiogenesis, pan-endothelial antibodies react with not only “newly forming” vessels but
also normal vessels just trapped within tumor tissues. It has been recently reported that anti-
CD105 antibody preferentially reacts with “activated” endothelial cells in angiogenic tissues.
Thus, the superiority of anti-CD105 monoclonal antibody (mAb) in evaluation of …
Abstract
Purpose: Angiogenesis is an essential process in the progression of malignant tumors. Whereas pan-endothelial markers, such as CD34, are generally used in evaluation of angiogenesis, pan-endothelial antibodies react with not only “newly forming” vessels but also normal vessels just trapped within tumor tissues. It has been recently reported that anti-CD105 antibody preferentially reacts with “activated” endothelial cells in angiogenic tissues. Thus, the superiority of anti-CD105 monoclonal antibody (mAb) in evaluation of angiogenesis of non-small cell lung cancer (NSCLC) was assessed.
Experimental Design: A total of 236 patients with resected NSCLC were retrospectively reviewed. Intratumoral microvessel density (IMVD) was determined with an anti-CD34 mAb (CD34-IMVD) and with an anti-CD105 mAb (CD105-IMVD).
Results: The mean CD34-IMVD and CD105-IMVD were 179.9 and 41.6, respectively. Whereas CD34-IMVD was significantly correlated with the expression of vascular endothelial growth factor (P = 0.003), CD105-IMVD was more closely correlated with vascular endothelial growth factor expression (P < 0.001). The 5-year survival rate of the lower CD105-IMVD patients was 74.9%, significantly higher than that of the higher CD105-IMD patients (60.4%, P = 0.018). Whereas the 5-year survival rate of the lower CD34-IMVD patients seemed higher than that of the higher CD34-IMVD patients (63.7%), the difference did not reach a statistical significance (P = 0.137). Multivariate analysis confirmed that higher CD105-IMVD was a significant factor to predict poor prognosis (P = 0.029), whereas CD34-IMVD was not (P = 0.070).
Conclusions: Anti-CD105 mAb proved to be superior to anti-CD34 mAb in evaluation of angiogenesis in NSCLC.
AACR